Search / 9 results found

from
to

SEATTLE and VANCOUVER, British Columbia, March 13, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2019 financial results and provided an update on the cytisinicline clinical development program.

SEATTLE and VANCOUVER, British Columbia, March 13, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2019 financial results and provided an update on the cytisinicline clinical development program.

SEATTLE and VANCOUVER, British Columbia, Feb. 6, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has retained the FreeMind Group, an international consulting firm dedicated to assisting life science organizations secure non-dilutive funding.

SEATTLE, Jan. 13, 2020 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has closed the 2(nd) tranche of its Series C round of financing. The proceeds of the financing are being used to support further clinical testing and commercialization of its Valeda(®) Light Delivery System for the treatment of dry Age-related Macular Degeneration (AMD).

SEATTLE, Jan. 13, 2020 /CNW/ -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has closed the 2(nd) tranche of its Series C round of financing. The proceeds of the financing are being used to support further clinical testing and commercialization of its Valeda(®) Light Delivery System for the treatment of dry Age-related Macular Degeneration (AMD).

VANCOUVER, Wash., Jan. 13, 2020 /PRNewswire/ -- AbSci, the Protein Printing(TM) company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciences. Existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Columbia Ventures Corporation also participated in the financing. The financing also includes $5M in term debt. The proceeds from the financing will be used for expansion of AbSci facilities and team in order to meet commercial demand for AbSci's technology.

Douglas County plans to build a new law and justice facility to house the Douglas County Sheriff’s Office, District Court, juvenile probation, information technology infrastructure and future coroner.